Eli Lilly and Company’s competing weight-loss drug, Zepbound (tirzepatide), could post over $11 billion in sales; Mounjaro ... OrbiMed, Logos Capital, Lilly Asia Ventures, and Lyfe Capital.

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going ...

An array of pharmaceutical pills with the company's logo on the bottle. Number of Hedge Fund Holders ... Key contributors ...

There's growing evidence to suggest that GLP-1 drugs, which include semaglutide, may be useful for treating alcohol use disorder.

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Court rulings against parts of Donald Trump's agenda put White House officials on the defensive. Hamas says it will not ...

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

While reporting financial results for the fourth quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, ...

Whoopi Goldberg took to The View to blast a "phony" AI weight loss ad running on social media that is using her image to ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.